What is InspireMD?
InspireMD, Inc. operates at the intersection of advanced engineering and clinical medicine, specializing in the development of the MicroNet stent platform. This proprietary technology is engineered to address the complexities of vascular and coronary diseases, with a primary focus on improving acute clinical results and ensuring durable, stroke-free long-term outcomes for patients. Listed on the NYSE American under the ticker NSPR, the company maintains a robust research and development presence in Israel, where it focuses on refining its stent architecture to mitigate the risks associated with traditional carotid stenting. By prioritizing high-precision medical device manufacturing, InspireMD seeks to capture significant market share within the cardiovascular intervention sector, positioning itself as a key player in the evolution of minimally invasive vascular therapies.
How much funding has InspireMD raised?
InspireMD has raised a total of $109.1M across 3 funding rounds:
Debt
$11M
Stock/Share Issuance
$40.1M
Stock/Share Issuance
$58M
Debt (2012): $11M, investors not publicly disclosed
Stock/Share Issuance (2025): $40.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $58M supported by OrbiMed
Key Investors in InspireMD
OrbiMed
OrbiMed Advisors LLC is a premier investment firm dedicated exclusively to the healthcare sector, providing capital and strategic guidance to companies across the biopharmaceutical, medical device, and digital health landscapes. The firm leverages deep life sciences expertise to support innovation from early-stage development through to commercial maturity.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for InspireMD?
With the recent infusion of capital, InspireMD is poised to execute its next phase of strategic expansion, focusing on the widespread adoption of its MicroNet platform. The company is expected to prioritize clinical validation and market penetration, leveraging its recent financing to support large-scale commercialization efforts. Future growth will likely hinge on the firm's ability to demonstrate superior long-term patient outcomes compared to existing market alternatives, thereby driving adoption among interventional cardiologists and vascular surgeons. Furthermore, the company will likely continue to optimize its supply chain and manufacturing capabilities to meet the anticipated demand for its specialized stent solutions. As InspireMD navigates this growth phase, the focus remains on maintaining its competitive edge through continuous innovation and strategic partnerships within the global healthcare ecosystem.
See full InspireMD company page
